WallStreetZenWallStreetZen

NASDAQ: GNLX
Genelux Corp Stock

$2.41-0.05 (-2.03%)
Updated Jun 12, 2024
GNLX Price
$2.41
Fair Value Price
$0.29
Market Cap
$65.06M
52 Week Low
$2.22
52 Week High
$40.98
P/E
-2.48x
P/B
4.31x
P/S
21,580.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.00k
Earnings
-$25.78M
Gross Margin
100%
Operating Margin
-321,912.5%
Profit Margin
-322,287.5%
Debt to Equity
0.64
Operating Cash Flow
-$20M
Beta
1.28
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

GNLX Overview

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GNLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GNLX ($2.41) is overvalued by 736.87% relative to our estimate of its Fair Value price of $0.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GNLX ($2.41) is not significantly undervalued (736.87%) relative to our estimate of its Fair Value price of $0.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GNLX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GNLX due diligence checks available for Premium users.

Be the first to know about important GNLX news, forecast changes, insider trades & much more!

GNLX News

Valuation

GNLX fair value

Fair Value of GNLX stock based on Discounted Cash Flow (DCF)
Price
$2.41
Fair Value
$0.29
Overvalued by
736.87%
GNLX ($2.41) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GNLX ($2.41) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GNLX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GNLX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.48x
Industry
-9.14x
Market
30.03x

GNLX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.31x
Industry
6.31x
GNLX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GNLX's financial health

Profit margin

Revenue
$8.0k
Net Income
-$7.9M
Profit Margin
-98,125%
GNLX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GNLX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$24.7M
Liabilities
$9.6M
Debt to equity
0.64
GNLX's short-term assets ($21.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GNLX's short-term assets ($21.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GNLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.4M
Investing
-$1.7M
Financing
$688.0k
GNLX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GNLX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
GNLX$65.06M-2.03%-2.48x4.31x
INAB$64.86M+5.00%-1.62x3.70x
CDTX$65.55M+6.05%-1.78x-3.69x
ATRA$65.63M-3.02%-0.26x-0.67x
TSBX$65.68M-1.73%-0.31x0.82x

Genelux Stock FAQ

What is Genelux's quote symbol?

(NASDAQ: GNLX) Genelux trades on the NASDAQ under the ticker symbol GNLX. Genelux stock quotes can also be displayed as NASDAQ: GNLX.

If you're new to stock investing, here's how to buy Genelux stock.

What is the 52 week high and low for Genelux (NASDAQ: GNLX)?

(NASDAQ: GNLX) Genelux's 52-week high was $40.98, and its 52-week low was $2.22. It is currently -94.12% from its 52-week high and 8.56% from its 52-week low.

How much is Genelux stock worth today?

(NASDAQ: GNLX) Genelux currently has 26,996,740 outstanding shares. With Genelux stock trading at $2.41 per share, the total value of Genelux stock (market capitalization) is $65.06M.

Genelux stock was originally listed at a price of $6.15 in Jan 26, 2023. If you had invested in Genelux stock at $6.15, your return over the last 1 years would have been -60.81%, for an annualized return of -60.81% (not including any dividends or dividend reinvestments).

How much is Genelux's stock price per share?

(NASDAQ: GNLX) Genelux stock price per share is $2.41 today (as of Jun 12, 2024).

What is Genelux's Market Cap?

(NASDAQ: GNLX) Genelux's market cap is $65.06M, as of Jun 13, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Genelux's market cap is calculated by multiplying GNLX's current stock price of $2.41 by GNLX's total outstanding shares of 26,996,740.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.